TO THE EDITOR
Essential thrombocythemia (ET), characterized by elevated platelet count with increased tendency to thrombosis and hemorrhage, lacks features diagnostic for other myeloproliferative disorders including the Philadelphia (Ph þ ) chromosome translocation. 1 The clinical course of ET shows a low rate of transformation to acute leukemia, even when the onset of the disease occurs at a young age. 2 We report a 38-year-old Caucasian female who presented 15 years ago with an asymptomatic platelet count 41000 Â 10 9 /l, a normal hematocrit and hemoglobin, and normal white blood cell count, without evidence of basophilia. The patient's clinical and laboratory parameters, and the bone marrow exam, which showed clustered mature and enlarged megakaryocytes and normal iron stores, met the diagnostic criteria for ET.
1
Cytogenetic study of two separate bone marrow aspirations performed at presentation showed 38 metaphases with a normal karyotype, one with monosomy 6, and one with monosomy 22. She remained asymptomatic for 13 years, on 81 mg of aspirin daily. She experienced lower back pain with immature cells in the peripheral blood 2 years ago. A bone marrow exam showed increased blasts (13%) with clusters of megakaryocytes showing morphologic features similar to those present in the original ET bone marrow. Flow cytometry identified two blast populations, one lymphoid with myeloid antigens (CD34 þ , CD19 þ , CD22 þ , CD10 þ , HLA-DR þ , CD33 þ dim) and one myeloid Bone marrow cytogenetics showing the karyotype 45,XX,À7,t(9;22)(q34;q11.2) in 12 of 20 metaphases at the time of leukemic transformation after 13 years without exposure to chemotherapy.
Cytogenetics revealed the presence of a Ph þ chromosome, with 12 of 20 metaphases showing a karyotype 45,XX,À7,t(9;22)(q34;q11.2) (Figure 1 ). The presence of a bcr/ abl gene rearrangement, b3a2, was detected by the polymerase chain reaction (PCR, data not shown). FISH studies on archival samples from the bone marrow obtained 15 years ago failed to show hybridization signals for the translocation t(9;22). After 3 months of imatinib mesylate (600 mg/day), a bone marrow examination revealed no evidence of leukemia, normal cytogenetics, but the bcr/abl transcript was still detectable by PCR. She underwent allogeneic stem cell transplantation from an HLA-compatible brother, using reduced-intensity conditioning with busulfan and fludarabine.
3 Platelet recovery occurred 10 days following stem cell infusion (day þ 10), neutrophilic recovery day þ 18, partial XY donor engraftment day þ 30 (89%), and full donor chimera day þ 150. The patient remains with normal blood counts and full donor hematopoiesis, without bcr/abl transcript detectable by PCR at day þ 800. She has limited mucocutaneous chronic graft-versus-host disease (GvHD) and 90% Karnofsky performance status.
The recently presented study by the Medical Research Council confirms the low rate of leukemic conversion in ET, reporting 10 cases of acute leukemia or myelodysplasia in 809 patients treated with hydroxyurea or anagrelide.
4 Even more uncommon is ET evolving to acute leukemia with a Ph þ complex karyotype, and without prior exposure to chemotherapy or radioactive 32 P, 5-6 as seen in our patient. The aneuploidy (loss of chromosomes 6 and 22) at diagnosis, and the 15-year interval between ET and leukemia, could indicate that a favorable bone marrow environment for leukemic transformation depends more on disease biology and duration, than on specific therapy.
7-8 The current availability of targeted therapy with imitanib mesylate allowed cytoreduction with decreased morbidity, and the reduced-intensity fludarabine-based program 3 allowed donor engraftment with curative intent in the context of chronic GvHD. The ETV6 gene is located on 12p13 and expressed as a 452 amino-acid protein with two regions of homology to the ETS family of transcription factors. It may be fused to various partner genes mainly coding for tyrosine kinases or transcription factors. In rare cases, it is rearranged with the ABL1 gene, producing two types of oncogenetic proteins with increased tyrosine kinase activity in vitro.
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2 The low incidence of ETV6/ABL1 gene fusion in leukemia might be attributed to the opposite orientation of both genes necessitating at least three chromosomal breaks to generate a functional fusion gene.
3,4
The clinical and morphologic presentation of ETV6/ABL1-positive leukemias is heterogenous, but eosinophilia may be a hallmark of the disease. 5 We here describe a new case of atypical myeloproliferative disorder with a cryptic ETV6/ABL1 fusion transcript detected by broad molecular screening with a multiplex RT-PCR system (HemaVisiont) and confirmed by molecular cytogenetic investigations.
A 65-year-old woman presented in April 2000 with abdominal and thoracic pain. Her history revealed a previous radical
